Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04725942
Other study ID # 20200909
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 2021
Est. completion date April 2023

Study information

Verified date January 2021
Source Institute of Hematology & Blood Diseases Hospital
Contact Aiming Pang
Phone +86-13820398091
Email pangaiming@ihcams.ac.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This open, prospective, observational multicenter cohort study aims to evaluate the efficacy, safety as well as the effective serum concentration of Posaconazole for prevention of pulmonary fungal infections in patients with hematopoietic stem cell transplantation. The correlation of UGT1A4*3 genotype and Cmin of Posaconazole, as well as invasive fungal disease (IFD) breakthrough rates will be utilized to evaluate the efficacy while the safety of Posaconazole will be assessed by the overall incidence and severity of adverse events in patients.


Description:

This open, prospective, observational multicenter cohort study aims to study the efficacy, safety and effective concentration of Posaconazole tablets for prevention of pulmonary fungal infection in patients with hematopoietic stem cell transplantation. A total of 360 hematopoietic stem cell transplantation patients receiving Posaconazole tablets are expected to be enrolled. Posaconazole tablets will be taken orally from the day of transplantation (300 mg Q12h D1) followed by 300 mg Qd, until 90 days after transplantation. The total duration of the study is estimated to be 24 months, with each patient participating for an estimated 3 months. The relationships between UGT1A4*3 genotype and drug serum concentration, IFD incidence, Aspergillus infection rate, IFD-related mortality rate, IFD-free survival rate, and overall survival rate will be used to evaluate the effectiveness of Posaconazole tablets in preventing invasive pulmonary fungal infection in patients with hematopoietic stem cell transplantation. Safety of Posaconazole tablet will be validated by the overall incidence and severity of adverse events in patients.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 360
Est. completion date April 2023
Est. primary completion date April 2023
Accepts healthy volunteers No
Gender All
Age group 13 Years and older
Eligibility Inclusion Criteria: - Age = 13 years old - The primary causes of hematopoietic stem cell transplantation include aplastic anemia, acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, or other hematologic diseases in patients pretreated for hematopoietic stem cell transplantation. The types of transplantation include autologous transplantation, syngeneic transplantation, matched sibling donor transplantation, unrelated donor transplantation and haploidentical transplantation - The patients themselves or their authorized clients agree to participate in the clinical study and sign the informed consent Exclusion Criteria: - Those with evidence of active fungal infection within 3 weeks prior to enrollment - Allergic to azole drugs - Severe abnormal liver function - Rifampicin, isoniazid, phenytoin, carbamazepine, and long-acting barbiturates were used in combination during the study - Any predictably increased patient risk or other factors that might interfere with the outcome of a clinical trial

Study Design


Intervention

Drug:
Oral Posaconazole tablets
Posaconazole tablets (300 mg Q12h D1) taken orally on the day of transplantation, and followed by 300mg Qd, until 90 days after transplantation.

Locations

Country Name City State
China The Second Hospital of Hebei Medical University Shijia Zhuang
China Shanxi Bethune Hospital Taiyuan
China Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Tianjin
China Tianjin Medical University Cancer Institute and Hospital Tianjin

Sponsors (4)

Lead Sponsor Collaborator
Institute of Hematology & Blood Diseases Hospital Shanxi Bethune Hospital, The Second Hospital of Hebei Medical University, Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary UGT1A4*3 genotype and plasma concentration of posaconazole Blood samples were drawn at baseline (day 0) for analysis of patients' UGT1A4*3 genotypes and assigned to homozygous, wild-type, and heterozygous genotypes. For posaconazole serum concentrations, blood samples were collected at day 0, 4, 8, 15 and 22. From day 0 to day 22
Secondary The incidence of invasive fungal disease (IFD) and the incidence of Aspergillus infection Patients who developed invasive fungal infections, aspergillus infections or death related with IFD infections during posaconazole prophylaxis treatment were recorded in accordance with IFD diagnostic guidelines (Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020 Sep 12;71(6):1367-1376). 90 days posaconazole prophylaxis and 7 days after prophylaxis ending
Secondary Plasma concentration of the patients who received different dosages of posaconazole as prophylaxis at different time points Blood samples were drawn from patients at day 0, 4, 8, 15, and 22 after receiving posaconazole. Day 0, 4, 8, 15 and 22
Secondary The influence of other combined medications for posaconazole plasma concentrations Blood samples were drawn at day 0, 4, 8, 15 and 22 after receiving posaconazole, while all combined medications during posaconazole prophylaxis were recorded and IFD cases were monitored during the study period. Duration of 90-day posaconazole prophylaxis
Secondary Effect of GVHD grading on absorption and utilization of posaconazole tablets (plasma concentration) Gastrointestinal GVHD grades (I-IV) were recorded according to patient symptoms and posaconazole plasma concentrations were measured using blood samples of each patient after receiving posaconazole tablets at day 0, 4, 8, 15 and 22. Duration of 90-day posaconazole prophylaxis
Secondary Effect of diarrhea on absorption and utilization of posaconazole tablets (plasma concentration) Diarrhea (acute watery diarrhea, acute hemorrhagic diarrhea, persistent diarrhea, and diarrhea with severe malnutrition) was recorded according to patient symptoms, and posaconazole plasma concentrations were measured using blood samples of each patient after receiving posaconazole tablets at day 0, 4, 8, 15 and 22. Duration of 90-day posaconazole prophylaxis
Secondary Number/Proportion of patients with immunosuppressive agent application and adjustments Recording of the number/proportion of patients who received immunosuppressive agents or adjustments of agents. Duration of 90-day posaconazole prophylaxis
Secondary Measurement and record of neutrophil counts Measurement of neutrophils in blood samples of patients. Duration of 90-day posaconazole prophylaxis
Secondary Measurement and record of duration of neutropenia Measurement of duration of neutropenia in blood samples of patients. Duration of 90-day posaconazole prophylaxis
Secondary Adverse events Record of the number, incidence and frequency of adverse events (AE) during the study period and judge whether the AE is drug related, serious, or special interest AE. AE severity is determined according to MedDRA v23.1. Duration of 90-day posaconazole prophylaxis
See also
  Status Clinical Trial Phase
Completed NCT01823289 - An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections Phase 4
Available NCT05897294 - Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis